Prostate-Specific Membrane Antigen (PSMA)

Statistics show that prostate cancer is the second most common cancer among men and ranks third after lung and breast cancer in terms of malignancy.The new methods of prostate cancer treatment have been able to create huge changes.
Prostate-Specific Membrane Antigen (PSMA) is a very specific molecular marker for diagnosing and treating the disease. Today, special radio ligands are used to target and bind to prostate-specific antigens, known as PSMA scanning. The results of this method are very promising, even in advanced stages of cancer. Two structures of the best peptide ligands used in PSMA scanning after labeling are PSMA-11 and PSMA-617, which are widely used in diagnostic and therapeutic processes, respectively.